North America Veterinary Healthcare Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

North America Veterinary Healthcare Market Trends and Insights

Growth in Companion Animal Ownership

Pet-owning households continue to climb, reaching 70 million in the United States in 2024 and 7.9 million in Canada, with Mexico showing 70% household penetration^{[1]American Veterinary Medical Association, “Pet Ownership Statistics 2025,” avma.org}. Younger owners increasingly adopt multiple pets at once, compressing routine-care cycles and straining under-staffed clinics. This intensifies demand for efficiency-enhancing POC diagnostics that deliver results during the same visit. Scheduling backlogs, particularly for wellness appointments, are steering corporate groups to extend weekend hours and to offer teletriage options that direct non-urgent cases to virtual platforms.

Increasing Pet Healthcare Expenditure

U.S. veterinary-care outlays grew from USD 39.8 billion in 2024 to USD 41.4 billion in 2025, while Canada allocated CAD 2.1 billion to veterinary services in 2023. Corporate groups segment offerings into tiered wellness packages versus high-acuity specialties, capturing both price-sensitive and premium spend without cannibalization. Although pet insurance premiums reached USD 4.7 billion in 2024, 94% of veterinarians still cite cost as a barrier to recommended care, signaling that coverage skews toward affluent clients^{[2]North American Pet Health Insurance Association, “2025 Industry Report,” naphia.org}.

Advancements in Veterinary Diagnostics and Therapeutics

POC hematology analyzers such as IDEXX ProCyte One and Heska Element HT5 now deliver CBCs in minutes, eliminating three-day laboratory waits. Next-generation sequencing panels frequently identify actionable mutations in 90% of canine and feline oncology specimens, accelerating the uptake of targeted therapy. Therapeutic pipelines are likewise advancing; FDA approval of Zoetis’ Librela in 2025 marked the first monoclonal antibody to modify the progression of canine osteoarthritis. Multi-agent oral parasiticides, such as Elanco’s Credelio Quattro, address owner compliance by replacing multi-product regimens with single chewables.

Rising Adoption of Pet Insurance

Policies covered 6.3 million U.S. pets in 2024, yet penetration remains under 7%. Insured clients approve higher-margin imaging, oncology, and surgical cases at greater rates, shifting clinic case-mix toward revenue-dense procedures. However, coverage continues to cluster in suburban and urban regions; rural areas lag due to lower average income and limited insurer marketing.

Shortage of Veterinary Professionals

The AVMA projects a 15,000-veterinarian deficit by 2030, while Canada anticipates a 1,500-practitioner shortfall. Debt-to-income imbalance discourages graduates from rural practice ownership, concentrating talent in urban centers and raising wait times for elective care. Corporate consolidators are bidding up salaries with sign-on bonuses and loan-repayment packages, but the measures mostly re-shuffle existing clinicians rather than expand total supply. Burnout, driven by moral distress and long hours, further erodes retention.

High Cost of Advanced Veterinary Care

Emergency visits average USD 1,000-2,000 in the United States, while specialty oncology consults can exceed USD 5,000. Insurance scarcity leaves owners to self-fund high-ticket procedures, producing case deferrals that undermine clinic profitability. In Mexico, annual dog maintenance runs 15,000-35,000 MXN (USD 800-1,900), with inflation at 8.15% as of September 2025, intensifying price sensitivity. Low-cost entrants such as Farmacias Similares’ SimiPet Care demonstrate that sub-USD 10 consultations can unlock latent demand when traditional fees exceed household budgets.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Diagnostics Gain Share as Therapeutics Plateau

Diagnostics revenue is poised to climb at a 6.43% CAGR, eclipsing therapeutic growth as practices embrace in-clinic molecular platforms that accelerate decision-making and generate consumable pull-through. SNAP immunoassays for heartworm and tick-borne panels are now featured in 80% of U.S. wellness visits, anchoring recurring kit sales that bolster the North American veterinary healthcare market for diagnostic consumables. Therapeutics continue to dominate absolute value; however, antimicrobial resistance constraints and heightened regulatory oversight temper volume expansion. Combination parasiticides, such as Simparica Trio and Credelio Quattro, demonstrate that convenience drives owner adherence, mitigating revenue leakage from missed doses. Within vaccines, livestock operators favor multivalent formulations that reduce handling stress, while companion-animal updates now incorporate chimeric technologies for broader strain coverage.

By Animal Type: Companion Animals Dominate, Poultry Drives Growth

Companion animals retain 45.78% revenue in 2025, reflecting entrenched pet-humanization behaviors that propel specialty referrals and chronic-disease management. Nevertheless, poultry health spending will outpace all other categories, expanding at 6.66% CAGR on the back of post-HPAI biosecurity upgrades and stricter export certification rules. Diagnostic laboratories report a surge in avian PCR panels, while vaccine suppliers ramp production to meet flock-wide prophylaxis mandates. Ruminant uptake remains constrained by commodity-price volatility; however, screwworm-related trade disruptions are spurring cattle operators to integrate parasiticides and serology screens to regain U.S. market access.

By Route of Administration: Oral Gains on Compliance

Parenteral products represented 46.54% revenue in 2025, but oral formats are set to climb at 6.12% CAGR through 2031, leveraging owner preference for at-home dosing convenience. Chewable parasiticides and flavored analgesics now command merchandising space at hospital checkout counters, directly boosting pharmacy-front sales. Practices benefit from reduced injection labor, yet the heightened non-compliance risk necessitates follow-up reminder systems to ensure dose completion, safeguard therapeutic outcomes, and minimize resistance development.

By End User: Point-of-Care Disrupts Reference Labs

Veterinary hospitals and clinics continue to anchor demand, yet POC and in-house testing settings will grow fastest at 7.12% CAGR. Analyzers financed via reagent-rental models lower upfront CAPEX, enticing mid-volume practices to internalize chemistry, hematology, and serology workflows. Reference labs respond with a broader menu and courier service guarantees, reserving complex histopathology and endocrinology assays for cases where economies of scale remain decisive. Hybrid testing models—IDEXX’s SDMA kidney biomarker, available both in-house and through labs—offer practices flexibility between turnaround time and breadth.

Geography Analysis

The United States accounted for 78.54% of 2025 revenue, underpinned by USD 41.4 billion in veterinary care spend and USD 4.7 billion in pet insurance premiums. FDA-mandated stewardship of antibiotics rechannels demand toward vaccines and POC pathogen screens, while workforce shortages elevate clinician salaries and incentivize telemedicine adoption for triaging routine follow-ups.

Canada’s share trails at roughly 14%, yet household pet ownership at 58% fuels steady clinic traffic, and CAD 2.1 billion in veterinary services underscores the country’s alignment with U.S. care standards^[3]. Veterinary school capacity constraints and an aging practitioner base sustain vacancy rates, encouraging cross-border recruiting and licensing harmonization initiatives.

Mexico, expanding at 7.21% CAGR, emerges as the fastest-growing geography despite sub-1% insurance penetration. The screwworm-driven cattle export ban sharpened focus on biosecurity compliance, accelerating uptake of parasiticides and lab diagnostics. Farmacias Similares’ rollout of low-cost SimiPet Care clinics—charging 100 MXN for consultations—confirms latent demand among middle-income households that have been historically priced out of premium operators. Multinational investment, exemplified by Mars’ MXN 3,500 million plant expansion, validates the long-term growth thesis.

Regulatory Landscape

North American veterinary healthcare is shaped by drug, biologics, and animal movement and import controls that affect time-to-market and commercialization costs. In the United States, USDA APHIS Center for Veterinary Biologics (CVB) oversees veterinary biologics (including inspection and compliance expectations), while federal import rules (for example, restrictions in 9 CFR Part 94 for animal products) interact with disease-driven trade measures. In June 2026, USDA APHIS issued updated import restrictions for specific avian zones in Alberta and Saskatchewan tied to HPAI, underscoring the operational importance of zone-based compliance for poultry and related diagnostics.

Regulatory processes are also moving toward digital-first submissions and lifecycle oversight. USDA APHIS published NCAH Portal user guides in January 2026 to support veterinary biologics submissions and licensing procedures, and CVB continued publishing updated catalog and organizational materials in April 2026. In Canada, Health Canada implemented a policy-based terms and conditions (T&Cs) approach for veterinary drugs in February 2025 to enable conditional market access for critical therapies, and opened a public consultation in December 2025 on revised draft guidance (concluding February 2026), indicating more structured use of conditional authorization pathways alongside evolving submission requirements.

Value Chain Analysis

The value chain covers discovery and formulation (innovator pharma and specialty biotech), regulated manufacturing and quality control, cold-chain dependent logistics (notably for vaccines and other biologics), wholesale distribution, and dispensing through veterinary hospitals, clinics, and emerging point-of-care and retail-service channels. Large manufacturers such as Zoetis, Elanco, Merck Animal Health, and Boehringer Ingelheim supply a mix of therapeutics and diagnostics that flows through value-added distributors and practice networks, while procurement scale is increasingly concentrated as corporate groups standardize formularies and testing menus across multi-site footprints.

Distribution and channel execution are becoming differentiators as consolidators seek predictable availability and negotiated pricing across thousands of sites. Covetrus renewed its distribution partnership with National Veterinary Associates in January 2024, supporting supply to more than 1,000 NVA hospitals in the United States and illustrating how contracted distribution supports on-shelf continuity for in-clinic products and consumables. Upstream, partnerships such as Elanco and Medgene (February 2025) to commercialize an HPAI vaccine platform for U.S. dairy cattle, and Longhorn Vaccines and Diagnostics with Promega (July 2025) for integrated molecular testing workflows, show how co-development and co-marketing are used to shorten commercialization cycles and expand access to specialized testing and prevention tools. Across the chain, reliance on globally sourced APIs and equipment increases exposure to tariff and transport disruptions, while cold-chain integrity remains a key operational constraint for biologics.

Market Opportunities and Future Outlook

Opportunities are concentrating around three clear whitespace areas: (1) faster diagnosis and workflow automation inside clinics, (2) scalable access models for routine care, and (3) differentiated alternatives to traditional antimicrobials. On the diagnostics side, Zoetis entered an agreement in July 2026 to acquire VitalRADS, a veterinary teleradiology platform, which aligns with the move toward distributed specialist capacity as case volumes rise and clinician time tightens. It also complements the shift toward point-of-care and in-house testing, where analyzer placements support recurring consumables pull-through and reduce dependence on reference laboratory turnaround for routine cases.

Service delivery expansion is also creating openings for suppliers that can support standardized protocols, integrated pharmacy fulfillment, and subscription-like preventive care bundles across large footprints. Tractor Supply Company acquired VIP Petcare from PetIQ in May 2026 to bring mobile in-store veterinary clinic operations in-house, and Bond Vet and Small Door Veterinary finalized a merger in July 2026 to form a network of more than 55 premium clinics, reflecting continued investment in scaled, tech-enabled care models. On the therapeutics side, FDA CVM actions in early 2026, including approvals of first generics (for example, robenacoxib tablets for cats) and emergency authorizations for specific animal health needs, point to a market environment where pricing tiers widen and where rapid-response regulatory mechanisms can accelerate access for high-impact disease events.